# Biotech Daily Digest — 2025-10-17

**48 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 9 items
- Fierce Biotech: 11 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 26 items


## Eli Lilly Press Releases

- **[Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment](https://investor.lilly.com/news-releases/news-release-details/lillys-verzenior-abemaciclib-prolonged-survival-hr-her2-high)**  
  _Fri, 17 Oct 2025 08:00:00 -0400_  
  Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the Phase 3 monarchE trial also show Verzenio plus endocrine therapy demonstrated sustained benefits in


## Endpoints News

- **[Roche inks $80M upfront deal for Hansoh’s cancer ADC](https://endpoints.news/roche-taps-hansohs-cancer-adc-for-80m-upfront/)**  
  _Fri, 17 Oct 2025 09:41:33 +0000_  
  Roche is spending $80 million upfront for global rights to Hansoh Pharma’s colorectal cancer candidate, which is an early-stage ADC that targets the CDH17 protein.

 Hansoh could get up to $1.45 billion in milestones, as ...

- **[British startup Genomics launches business to help drug developers](https://endpoints.news/british-startup-genomics-launches-business-to-help-drug-developers/)**  
  _Thu, 16 Oct 2025 19:34:15 +0000_  
  BOSTON — Over the past decade, the University of Oxford spinout Genomics has been collecting just about any human genetic data it can get its hands on. Now it is launching a new product to get ...

- **[Pregene lands up to $1.52B deal with Kite for in vivo therapies](https://endpoints.news/pregene-lands-up-to-1-52b-deal-with-kite-for-in-vivo-therapies/)**  
  _Thu, 16 Oct 2025 19:25:26 +0000_  
  Chinese biotech Pregene Biopharma has entered into a licensing pact with Gilead's Kite Pharma that could be worth as much as $1.52 billion, under a deal that looks to accelerate the development of next-generation  ...

- **[Pfizer CEO says US must compete better against China, not block it](https://endpoints.news/pfizer-ceo-says-us-must-compete-better-against-china-not-block-it/)**  
  _Thu, 16 Oct 2025 19:06:09 +0000_  
  Pfizer CEO Albert Bourla called China's biopharma ecosystem "remarkable," telling CNBC's Invest in America forum on Wednesday that the US should focus less on slowing down China and more on how ...

- **[FDA tells Supreme Court to pass on Vanda's fast-track status fight](https://endpoints.news/fda-tells-supreme-court-to-pass-on-vandas-fast-track-status-fight/)**  
  _Thu, 16 Oct 2025 16:47:56 +0000_  
  The FDA is urging the US Supreme Court not to take up a case over its denial of fast-track status for Vanda Pharmaceuticals’ experimental drug tradipitant.

 The case involves the FDA’s fast-track program, which is ...

- **[Merck KGaA is open to more acquisitions, but not for its CDMO unit](https://endpoints.news/merck-kgaa-is-open-to-make-more-acquisitions-but-not-for-its-cdmo-unit/)**  
  _Thu, 16 Oct 2025 15:18:38 +0000_  
  

- **[Praxis reports double wins in Phase 3 essential tremor trials, sending stock up](https://endpoints.news/praxis-reports-double-wins-in-phase-3-essential-tremor-trials-sending-stock-up/)**  
  _Thu, 16 Oct 2025 15:14:10 +0000_  
  Shares of Praxis Precision Medicines nearly tripled Thursday morning after it reported two Phase 3 wins, one in a trial that had been all but written off as a likely failure by an independent data ...

- **[What we’re watching at HLTH](https://endpoints.news/what-were-watching-at-hlth/)**  
  _Thu, 16 Oct 2025 15:06:28 +0000_  
  Ngai and I are prepping for Las Vegas, for what is sure to be an overwhelming couple of days at HLTH.

 If my calendar is any indication, it seems like a lot of newsmakers will ...

- **[Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer?](https://endpoints.news/are-pd-1xvegf-bispecifics-being-tested-in-the-wrong-kinds-of-cancer/)**  
  _Thu, 16 Oct 2025 14:47:42 +0000_  
  Summit Therapeutics is running late-stage trials for biopharma’s buzziest drug in lung cancer, but some industry experts believe ivonescimab and other PD-1xVEGF bispecifics may better target another type of tumor.

 They say a drug that ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/esmo-bms-confident-it-can-stay-ahead-competition-adcs-55-orr" hreflang="en">ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage trial</a>](https://www.fiercebiotech.com/biotech/esmo-bms-confident-it-can-stay-ahead-competition-adcs-55-orr)**  
  _Oct 17, 2025 9:37am_  
  Bristol Myers Squibb touted a 55% overall response rate from one cohort of an early-stage study of its EGFRxHER3 antibody-drug conjugate.

- **[<a href="https://www.fiercebiotech.com/biotech/unpacking-fda-transparency-push-crls" hreflang="en">Unpacking the FDA transparency push on CRLs</a>](https://www.fiercebiotech.com/biotech/unpacking-fda-transparency-push-crls)**  
  _Oct 17, 2025 9:41am_  
  The FDA made waves in early September when it announced a plan to publicly release complete response letters, or CRLs, at the same time they are issued to sponsoring companies. What risks and opportunities does this new policy pose for biopharma companies?

- **[<a href="https://www.fiercebiotech.com/pharma/big-pharma-bets-big-mash" hreflang="en">Big pharma bets big on MASH with a new combo playbook</a>](https://www.fiercebiotech.com/pharma/big-pharma-bets-big-mash)**  
  _Oct 14, 2025 1:30pm_  
  After Rezdiffra’s approval and Wegovy’s label expansion, the race is on in metabolic dysfunction-associated steatohepatitis. M&A deals totaling more than $10 billion in recent months show major pharma players still see sizable opportunity in the field.

- **[<a href="https://www.fiercebiotech.com/biotech/fda-names-regeneron-and-sanofi-among-first-recipients-1-2-month-priority-review-vouchers" hreflang="en">FDA names 9 first recipients of 1- to 2-month priority review vouchers</a>](https://www.fiercebiotech.com/biotech/fda-names-regeneron-and-sanofi-among-first-recipients-1-2-month-priority-review-vouchers)**  
  _Oct 17, 2025 4:50am_  
  The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and Sanofi to complete the approval process in one to two months.

- **[<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-cabaletta-corrals-cell-therapy-legend-commercial-chief" hreflang="en">Chutes &amp; Ladders—Cabaletta corrals cell therapy Legend as commercial chief</a>](https://www.fiercebiotech.com/biotech/chutes-ladders-cabaletta-corrals-cell-therapy-legend-commercial-chief)**  
  _Oct 16, 2025 4:14pm_  
  Just a few months after surfacing at Orca Bio following his early 2025 departure from Legend Biotech, Steve Gavel has taken on the chief commercial officer role at yet another cell therapy biotech. He is now CCO at Cabaletta Bio, effective immediately, where he brings a wealth of cell therapy experience.

- **[<a href="https://www.fiercebiotech.com/biotech/kite-puts-16b-line-pair-chinas-pregene-another-vivo-car-t-deal" hreflang="en">Kite puts $1.6B on the line to pair up with China's Pregene for another in vivo CAR-T deal</a>](https://www.fiercebiotech.com/biotech/kite-puts-16b-line-pair-chinas-pregene-another-vivo-car-t-deal)**  
  _Oct 16, 2025 4:57pm_  
  Gilead’s Kite Pharma is doubling down on in vivo CAR-T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma.

- **[<a href="https://www.fiercebiotech.com/biotech/we-can-have-tiktok-why-cant-we-have-drugs-nkarta-ceo-hastings-urges-us-drop-china-tariffs" hreflang="en">‘We can have TikTok. Why can’t we have drugs?’: Nkarta CEO Hastings warns against China biotech penalties</a>](https://www.fiercebiotech.com/biotech/we-can-have-tiktok-why-cant-we-have-drugs-nkarta-ceo-hastings-urges-us-drop-china-tariffs)**  
  _Oct 15, 2025 4:49pm_  
  As geopolitical tensions rise, Nkarta CEO Paul Hastings is urging the U.S. government not to impose restrictions on Chinese scientific collaboration and refocus on what matters most: the patient.

- **[<a href="https://www.fiercebiotech.com/biotech/praxis-bounces-back-shaky-ground-phase-3-win-essential-tremors-sending-stocks-soaring" hreflang="en">Praxis erases doubts with phase 3 wins in essential tremor, sending shares soaring</a>](https://www.fiercebiotech.com/biotech/praxis-bounces-back-shaky-ground-phase-3-win-essential-tremors-sending-stocks-soaring)**  
  _Oct 16, 2025 11:08am_  
  The trials demonstrated the benefits of Praxis' ulixacaltamide in essential tremor after a previously grim outlook at an interim analysis of one of the studies earlier this year.

- **[<a href="https://www.fiercebiotech.com/biotech/french-antibody-biotech-draws-122m-end-year-clinical-push" hreflang="en">French antibody biotech draws in $122M for end-of-year clinical push</a>](https://www.fiercebiotech.com/biotech/french-antibody-biotech-draws-122m-end-year-clinical-push)**  
  _Oct 16, 2025 10:59am_  
  French antibody specialist Adcytherix has added a €105 million ($122 million) series A to its coffers, which the Marseille-based biotech will use to push its lead antibody-drug conjugate into clinical trials.

- **[<a href="https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25" hreflang="en">Fierce Biotech Fundraising Tracker '25: Adcytherix adds $122M; Peptilogics pumps up with $78M</a>](https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25)**  
  _Dec 23, 2024 12:22pm_  
  The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

- **[<a href="https://www.fiercebiotech.com/biotech/dianthus-offers-1b-china-biotechs-autoimmune-pipeline-product" hreflang="en">Dianthus offers up to $1B for China biotech's autoimmune 'pipeline in a product'</a>](https://www.fiercebiotech.com/biotech/dianthus-offers-1b-china-biotechs-autoimmune-pipeline-product)**  
  _Oct 16, 2025 10:26am_  
  Dianthus Therapeutics is offering Nanjing Leads Biolabs up to $1 billion biobucks for licensing rights to a bifunctional fusion protein designed to treat certain autoimmune disorders.


## Regeneron Press Releases

- **[Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation](https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-recommended-eu-approval-chmp-adjuvant)**  
  _Fri, 17 Oct 2025 07:30:00 -0400_  
  Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p0.0001), the primary endpoint of the trial TARRYTOWN, N.Y. , Oct.


## arXiv q-bio

- **[A Two-Feature Quantitative EEG Index of Pediatric Epilepsy Severity: External Pre-Validation on CHB-MIT and Roadmap to Dravet Cohorts](https://arxiv.org/abs/2510.13815)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.13815v1 Announce Type: new 
Abstract: Objective biomarkers for staging pediatric epileptic encephalopathies are scarce. We revisited a large open repository -- the CHB-MIT Scalp EEG Database, 22 subjects aged 1.5-19 y recorded at 256 Hz under the 10-20 montage -- to derive and validate a compact quantitativ…

- **[GQVis: A Dataset of Genomics Data Questions and Visualizations for Generative AI](https://arxiv.org/abs/2510.13816)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.13816v1 Announce Type: new 
Abstract: Data visualization is a fundamental tool in genomics research, enabling the exploration, interpretation, and communication of complex genomic features. While machine learning models show promise for transforming data into insightful visualizations, current models lack t…

- **[Towards Neurocognitive-Inspired Intelligence: From AI's Structural Mimicry to Human-Like Functional Cognition](https://arxiv.org/abs/2510.13826)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.13826v1 Announce Type: new 
Abstract: Artificial intelligence has advanced significantly through deep learning, reinforcement learning, and large language and vision models. However, these systems often remain task specific, struggle to adapt to changing conditions, and cannot generalize in ways similar to…

- **[Hybrid Deep Learning Approaches for Classifying Autism from Brain MRI](https://arxiv.org/abs/2510.13841)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.13841v1 Announce Type: new 
Abstract: Autism spectrum disorder (ASD) is most often diagnosed using behavioral evaluations, which can vary between clinicians. Brain imaging, combined with machine learning, may help identify more objective patterns linked to ASD. This project used magnetic resonance imaging (…

- **[Large Language Model Agents Enable Autonomous Design and Image Analysis of Microwell Microfluidics](https://arxiv.org/abs/2510.13883)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.13883v1 Announce Type: new 
Abstract: Microwell microfluidics has been utilized for single-cell analysis to reveal heterogeneity in gene expression, signaling pathways, and phenotypic responses for identifying rare cell types, understanding disease progression, and developing more precise therapeutic strate…

- **[Dual-attention ResNet outperforms transformers in HER2 prediction on DCE-MRI](https://arxiv.org/abs/2510.13897)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.13897v1 Announce Type: new 
Abstract: Breast cancer is the most diagnosed cancer in women, with HER2 status critically guiding treatment decisions. Noninvasive prediction of HER2 status from dynamic contrast-enhanced MRI (DCE-MRI) could streamline diagnostics and reduce reliance on biopsy. However, preproce…

- **[OralGPT: A Two-Stage Vision-Language Model for Oral Mucosal Disease Diagnosis and Description](https://arxiv.org/abs/2510.13911)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.13911v1 Announce Type: new 
Abstract: Oral mucosal diseases such as leukoplakia, oral lichen planus, and recurrent
  aphthous ulcers exhibit diverse and overlapping visual features,
  making diagnosis challenging for non-specialists. While vision-language
  models (VLMs) have shown promise in medical image…

- **[Using Information Geometry to Characterize Higher-Order Interactions in EEG](https://arxiv.org/abs/2510.14188)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14188v1 Announce Type: new 
Abstract: In neuroscience, methods from information geometry (IG) have been successfully applied in the modelling of binary vectors from spike train data, using the orthogonal decomposition of the Kullback-Leibler divergence and mutual information to isolate different orders of i…

- **[Evolvable Chemotons: Toward the Integration of Autonomy and Evolution](https://arxiv.org/abs/2510.14282)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14282v1 Announce Type: new 
Abstract: In this study, we provide a relatively simple simulation framework for constructing artificial life (ALife) with both autonomous and evolutionary aspects by extending chemoton model. While the original chemoton incorporates metabolism, membrane, and genetic templates, i…

- **[Joint encoding of "what" and "when" predictions through error-modulated plasticity in reservoir spiking networks](https://arxiv.org/abs/2510.14382)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14382v1 Announce Type: new 
Abstract: The brain understands the external world through an internal model that generates predictions and refines them based on prediction errors. A complete prediction specifies what will happen, when it will happen, and with what probability, which we refer to as a "predictio…

- **[Viral population dynamics at the cellular level, considering the replication cycle](https://arxiv.org/abs/2510.14481)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14481v1 Announce Type: new 
Abstract: Viruses are microscopic infectious agents that require a host cell for replication. Viral replication occurs in several stages, and the completion time for each stage varies due to differences in the cellular environment. Thus, the time to complete each stage in viral r…

- **[Semantic representations emerge in biologically inspired ensembles of cross-supervising neural networks](https://arxiv.org/abs/2510.14486)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14486v1 Announce Type: new 
Abstract: Brains learn to represent information from a large set of stimuli, typically by weak supervision. Unsupervised learning is therefore a natural approach for exploring the design of biological neural networks and their computations. Accordingly, redundancy reduction has b…

- **[Nonlinear shift along the sensorimotor-association-axis in brain responses to task performance](https://arxiv.org/abs/2510.14601)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14601v1 Announce Type: new 
Abstract: In the literature of cognitive neuroscience, researchers tend to assume a linear relationship between brain activation level and task performance; however, controversial findings have been reported in participants at different ages and different proficiency levels. Ther…

- **[Cumulants, Moments and Selection: The Connection Between Evolution and Statistics](https://arxiv.org/abs/2510.14917)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14917v1 Announce Type: new 
Abstract: Cumulants and moments are closely related to the basic mathematics of continuous and discrete selection (respectively). These relationships generalize Fisher's fundamental theorem of natural selection and also make clear some of its limitation. The relationship between…

- **[cubic: CUDA-accelerated 3D Bioimage Computing](https://arxiv.org/abs/2510.14143)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14143v1 Announce Type: cross 
Abstract: Quantitative analysis of multidimensional biological images is useful for understanding complex cellular phenotypes and accelerating advances in biomedical research. As modern microscopy generates ever-larger 2D and 3D datasets, existing computational approaches are i…

- **[Propagation speed of traveling waves for diffusive Lotka-Volterra system with strong competition](https://arxiv.org/abs/2510.14311)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14311v1 Announce Type: cross 
Abstract: We study the propagation speed of bistable traveling waves in the classical two-component diffusive Lotka-Volterra system under strong competition. From an ecological perspective, the sign of the propagation speed determines the long-term outcome of competition betwee…

- **[Coder as Editor: Code-driven Interpretable Molecular Optimization](https://arxiv.org/abs/2510.14455)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14455v1 Announce Type: cross 
Abstract: Molecular optimization is a central task in drug discovery that requires precise structural reasoning and domain knowledge. While large language models (LLMs) have shown promise in generating high-level editing intentions in natural language, they often struggle to fa…

- **[Determining the optimal structural resolution of proteins through an information-theoretic analysis of their conformational ensemble](https://arxiv.org/abs/2311.08076)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2311.08076v5 Announce Type: replace 
Abstract: The choice of structural resolution is a fundamental aspect of protein modelling, determining the balance between descriptive power and interpretability. Although atomistic simulations provide maximal detail, much of this information is redundant to understand the r…

- **[Nonequilibrium physics of brain dynamics](https://arxiv.org/abs/2504.12188)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2504.12188v2 Announce Type: replace 
Abstract: Information processing in the brain is coordinated by the dynamic activity of neurons and neural populations at a range of spatiotemporal scales. These dynamics, captured in the form of electrophysiological recordings and neuroimaging, show evidence of time-irrevers…

- **[The cognitive triple-slit experiment](https://arxiv.org/abs/2505.05497)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2505.05497v3 Announce Type: replace 
Abstract: Quantum cognition has made it possible to model human cognitive processes very effectively, revealing numerous parallels between the properties of conceptual entities tested by the human mind and those of microscopic entities tested by measurement apparatuses. The s…

- **[Two Issues in Modelling Fish Migration](https://arxiv.org/abs/2509.00122)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2509.00122v2 Announce Type: replace 
Abstract: Fish migration is a dynamic phenomenon observed in many surface water bodies on the earth, while its understanding is still insufficient. Particularly, the biological mechanism behind fish migration is not fully understood. Moreover, its observation is often conduct…

- **[A contribution to discern the true impact of covid-19 on human mortality](https://arxiv.org/abs/2401.03875)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2401.03875v2 Announce Type: replace-cross 
Abstract: The years 2020 and 2021 were characterized by the COVID-19 pandemic. The true impact of the pandemic on populations' health and life still has to be fully discerned. The main objective of this work is to discern the true impact of COVID-19 pandemic in the EU c…

- **[Stabilization of active tissue deformation by a dynamic signaling gradient](https://arxiv.org/abs/2412.15774)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2412.15774v3 Announce Type: replace-cross 
Abstract: A key process during animal morphogenesis is oriented tissue deformation, which is often driven by internally generated active stresses. Yet, such active oriented materials are prone to well-known instabilities, raising the question of how oriented tissue defo…

- **[A data-driven analysis of the impact of non-compliant individuals on epidemic diffusion in urban settings](https://arxiv.org/abs/2506.13325)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2506.13325v3 Announce Type: replace-cross 
Abstract: Individuals who do not comply with public health safety measures pose a significant challenge to effective epidemic control, as their risky behaviours can undermine public health interventions. This is particularly relevant in urban environments because of the…

- **[VALID-Mol: a Systematic Framework for Validated LLM-Assisted Molecular Design](https://arxiv.org/abs/2506.23339)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2506.23339v2 Announce Type: replace-cross 
Abstract: Large Language Models demonstrate substantial promise for advancing scientific discovery, yet their deployment in disciplines demanding factual precision and specialized domain constraints presents significant challenges. Within molecular design for pharmaceut…

- **[Oligonucleotide selective detection by levitated optomechanics](https://arxiv.org/abs/2507.17940)**  
  _Fri, 17 Oct 2025 00:00:00 -0400_  
  arXiv:2507.17940v3 Announce Type: replace-cross 
Abstract: This study examines the detection of oligonucleotide-specific signals in sensitive optomechanical experiments. Silica nanoparticles were functionalized using ZnCl$_2$ and 25-mers of single-stranded deoxyadenosine and deoxythymidine monophosphate which were opt…
